Press Releases

Date Title and Summary
Toggle Summary First-in-Country TomoTherapy® Systems Operate in Thailand and the Philippines
TomoTherapy System Provides Patients Accurate and High Quality Individualized Treatments SUNNYVALE, Calif., May 24, 2012 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that Maharaj Nakorn Chiang Mai Hospital (‘Chiangmai University Hospital’) in Chiang
Toggle Summary Accuray and the German Cancer Research Center Sign Master Research and Collaboration Agreement
Latest Collaboration with Leading Research Institution Continues Partnership in New Technology Development ­ SUNNYVALE, Calif. , May 22, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today the signing of a multi-year master research and
Toggle Summary Accuray Appoints Richard Pettingill, LFACHE to Board of Directors
SUNNYVALE, Calif. , May 17, 2012 /PRNewswire/ --  Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today the appointment of Richard Pettingill , LFACHE as a member of the company's Board of Directors effective May 11, 2012 .
Toggle Summary Full Breadth and Depth of Accuray’s Advanced, Personalized Radiation Treatment Capabilities Showcased at ESTRO 31
Conference Presentations Highlighted Benefits of the CyberKnife® System’s Motion Management and the TomoTherapy® System’s Daily Image-Guidance SUNNYVALE, Calif., May 16, 2012 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that for the first time in
Toggle Summary Accuray Incorporated to Speak at B. Riley & Company 13th Annual Investor Conference
SUNNYVALE, Calif. , May 15, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that its management is scheduled to present at the B. Riley & Company 13th Annual Investor Conference in Los Angeles on Wednesday, May 23, 2012 at 11:30
Toggle Summary Accuray Unveils Enhanced TomoTherapy Treatment Planning System at ESTRO 31
New VoLO™ Technology Delivers Greater Efficiency and Flexibility in Complex Treatment Planning; Demonstrates Accuray's Ongoing Commitment to Advancing Radiation Oncology SUNNYVALE, Calif. , May 9, 2012 /PRNewswire/ --  Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company,
Toggle Summary Accuray Announces Results for Third Quarter Fiscal 2012
Continued Service Margin Improvement Highlights Quarter SUNNYVALE, Calif. , May 8, 2012 /PRNewswire/ --  Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today financial results for the third quarter of fiscal 2012 that ended March 31, 2012 .
Toggle Summary Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
New Randomized Study Aims to Provide Comparative Evidence to Support CyberKnife SBRT as the Gold Standard Treatment for Prostate Cancer SUNNYVALE, Calif., April 26, 2012 /PRNewswire via COMTEX/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today the
Toggle Summary Accuray Incorporated to Report Financial Results for Third Quarter of Fiscal 2012
SUNNYVALE, Calif. , April 9, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today announced that it will report results for its third quarter of fiscal year 2012, ended March 31, 2012 on Tuesday, May 8, 2012 after the market closes.
Toggle Summary Accuray Expands Treatment Options for Patients in Finland
CyberKnife Radiosurgery Provides Patients an Effective, Non-Invasive and Convenient Treatment Option SUNNYVALE, Calif., April 2, 2012 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that Kuopio University Hospital in Kuopio, Finland has begun treating

*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at https://investors.accuray.com/financial-information/sec-filings and on the SEC's website at www.sec.gov.